179 related articles for article (PubMed ID: 30793410)
1. Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.
Jacob Y; Rosenberg-Katz K; Gurevich T; Helmich RC; Bloem BR; Orr-Urtreger A; Giladi N; Mirelman A; Hendler T; Thaler A
Hum Brain Mapp; 2019 Jun; 40(8):2546-2555. PubMed ID: 30793410
[TBL] [Abstract][Full Text] [Related]
2. A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.
Bregman N; Thaler A; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N;
Brain Struct Funct; 2017 Apr; 222(3):1207-1218. PubMed ID: 27401793
[TBL] [Abstract][Full Text] [Related]
3. DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.
Artzi M; Even-Sapir E; Lerman Shacham H; Thaler A; Urterger AO; Bressman S; Marder K; Hendler T; Giladi N; Ben Bashat D; Mirelman A
PLoS One; 2017; 12(4):e0175424. PubMed ID: 28406934
[TBL] [Abstract][Full Text] [Related]
4. Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation.
Thaler A; Gonen T; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Bloem BR; Giladi N; Hendler T;
Brain Imaging Behav; 2019 Aug; 13(4):1009-1020. PubMed ID: 29971685
[TBL] [Abstract][Full Text] [Related]
5. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
[TBL] [Abstract][Full Text] [Related]
6. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.
Vilas D; Segura B; Baggio HC; Pont-Sunyer C; Compta Y; Valldeoriola F; José Martí M; Quintana M; Bayés A; Hernández-Vara J; Calopa M; Aguilar M; Junqué C; Tolosa E;
Mov Disord; 2016 Dec; 31(12):1820-1828. PubMed ID: 27653520
[TBL] [Abstract][Full Text] [Related]
7. Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.
Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Shenhar-Tsarfaty S; Mirelman A
J Neurol; 2021 Apr; 268(4):1517-1525. PubMed ID: 33388928
[TBL] [Abstract][Full Text] [Related]
8. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
Thaler A; Mirelman A; Helmich RC; van Nuenen BF; Rosenberg-Katz K; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T;
Cortex; 2013 Oct; 49(9):2501-11. PubMed ID: 23357204
[TBL] [Abstract][Full Text] [Related]
9. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
10. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.
Pont-Sunyer C; Iranzo A; Gaig C; Fernández-Arcos A; Vilas D; Valldeoriola F; Compta Y; Fernández-Santiago R; Fernández M; Bayés A; Calopa M; Casquero P; de Fàbregues O; Jaumà S; Puente V; Salamero M; José Martí M; Santamaría J; Tolosa E
PLoS One; 2015; 10(7):e0132368. PubMed ID: 26177462
[TBL] [Abstract][Full Text] [Related]
11. Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.
Thaler A; Helmich RC; Or-Borichev A; van Nuenen BF; Shapira-Lichter I; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T; Mirelman A;
Eur J Neurosci; 2016 Jan; 43(1):106-12. PubMed ID: 26536050
[TBL] [Abstract][Full Text] [Related]
12. Executive attention networks show altered relationship with default mode network in PD.
Boord P; Madhyastha TM; Askren MK; Grabowski TJ
Neuroimage Clin; 2017; 13():1-8. PubMed ID: 27896064
[TBL] [Abstract][Full Text] [Related]
13. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
[TBL] [Abstract][Full Text] [Related]
14. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
[TBL] [Abstract][Full Text] [Related]
15. A study of neural activity and functional connectivity within the olfactory brain network in Parkinson's disease.
Georgiopoulos C; Witt ST; Haller S; Dizdar N; Zachrisson H; Engström M; Larsson EM
Neuroimage Clin; 2019; 23():101946. PubMed ID: 31491835
[TBL] [Abstract][Full Text] [Related]
16. Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers.
van den Heuvel L; Lim AS; Visanji NP; Huang J; Ghate T; Mestre TA; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Pondal M; Faust-Socher A; Rogaeva E; Tomlinson G; Lang AE; Marras C
J Parkinsons Dis; 2018; 8(1):131-139. PubMed ID: 29480219
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.
Thaler A; Shenhar-Tsarfaty S; Shaked Y; Gurevich T; Omer N; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Giladi N; Mirelman A
Sci Rep; 2020 Jun; 10(1):9329. PubMed ID: 32518334
[TBL] [Abstract][Full Text] [Related]
18. Cortical and subcortical functional connectivity and cognitive impairment in Parkinson's disease.
Yeager BE; Twedt HP; Bruss J; Schultz J; Narayanan NS
Neuroimage Clin; 2024; 42():103610. PubMed ID: 38677099
[TBL] [Abstract][Full Text] [Related]
19. Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease.
Carricarte Naranjo C; Marras C; Visanji NP; Cornforth DJ; Sanchez-Rodriguez L; Schüle B; Goldman SM; Estévez M; Stein PK; Lang AE; Jelinek HF; Machado A
Clin Auton Res; 2019 Dec; 29(6):603-614. PubMed ID: 31444591
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 G2019S Parkinson's disease with more benign phenotype than idiopathic.
Ben Romdhan S; Farhat N; Nasri A; Lesage S; Hdiji O; Ben Djebara M; Landoulsi Z; Stevanin G; Brice A; Damak M; Gouider R; Mhiri C
Acta Neurol Scand; 2018 Nov; 138(5):425-431. PubMed ID: 29989150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
